OPERA: Excess Weight Gain Observed Immediately After Switch From TDF to TAF in Virologically Suppressed Adults Regardless of INSTI Use

July 6-10, 2020; Virtual
During the first 9 months following a switch from TDF- to TAF-based ART, estimated annual rates of weight gain ranged from 1.80-4.47 kg across regimens. These gains subsequently slowed or plateaued but occurred regardless of concomitant INSTI use.
Format: Microsoft PowerPoint (.ppt)
File Size: 307 KB
Released: July 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Merck Sharp & Dohme Corp.

Related Content

Clinical Care Options (CCO) slideset providing expert insights for ART management in complex clinical situations, including extensive previous treatment

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Eric S. Daar, MD
Released: July 1, 2022

person default Ariel Campos, MD person default Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Luis E. Soto-Ramirez, MD Released: June 30, 2022

Clinical Care Options (CCO) downloadable slides from Cristina Mussini, MD, providing practical insights into implementing long-acting ART into HIV care

Babafemi Taiwo, MBBS
Program Director
Cristina Mussini, MD
Released: June 14, 2022

Clinical Care Options (CCO) downloadable slides from Dr Darrell Tan, providing an overview of available long-acting ART for HIV treatment and prevention

Babafemi Taiwo, MBBS
Program Director
Darrell H. S. Tan, MD, FRCPC, PhD
Released: June 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings